Stemrim Inc. (4599) Press Release
Patent Registration in South Korea for Redasemtide in Cartilage Disorders
Earlier from Stemrim
- StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees
- StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
- StemRIM Announces Patent Registration for SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in South Korea
- StemRIM Announces Patent Registration (Mexico) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders